Ultimovacs Overview
- Founded
-
2011
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
ULTI
- Investments
-
2
- Share Price
-
$11.99
- (As of Wednesday Closing)
Ultimovacs General Information
Description
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
OSL
Primary Office
- Ullernchausséen 64
- 0379 Oslo
- Norway
+47 413 00 000
Ultimovacs Timeline
Ultimovacs Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $11.99 | $11.74 | $5.44 - $13.27 | $413M | 34.4M | 47.9K | -$0.47 |
Ultimovacs Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 142,834 | 398,244 | 251,846 | 78,800 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (17,578) | (19,103) | (12,911) | (7,313) |
| Net Income | (15,973) | (19,100) | (12,740) | (6,948) |
| Total Assets | 51,456 | 74,314 | 62,051 | 54,203 |
| Total Debt | 168 | 236 | 443 | 411 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ultimovacs Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ultimovacs Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product cand
Drug Discovery
Oslo, Norway
21
As of 2022
00000
000000000
00000
000000
s nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000 000000000
Oslo, Norway
00
As of 0000
0000000000 0
000000
niam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo co
0000 000000000
Vienna, Austria
00
As of 0000
000.00
0000000000 0
Add Comparison
Ultimovacs Competitors (10)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zelluna Immunotherapy | Venture Capital-Backed | Oslo, Norway | 00 | 0000000000 0 | ||
| 0000000 000000000 | Venture Capital-Backed | Vienna, Austria | 00 | 000.00 | 0000000000 0 | |
| 00000000 | Formerly VC-backed | Mainz, Germany | 0000 | 00.000 | 00000000 | 00.000 |
| 00000000 | Formerly VC-backed | Tubingen, Germany | 000 | 00000 | 000000000 | 00000 |
| 0000000 0000000000 | Venture Capital-Backed | Bedford, MA | 00 | 000.00 | 0000000000 0 | 000.00 |
Ultimovacs Patents
Ultimovacs Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2017275782-A1 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | Pending | 02-Jun-2016 | 00000000000 | |
| CA-3026172-A1 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | Pending | 02-Jun-2016 | 00000000000 | |
| EP-3463436-A1 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | Pending | 02-Jun-2016 | 0000000000000 | |
| US-20190247482-A1 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | Active | 02-Jun-2016 | 0000000000000 | |
| US-11419927-B2 | Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | Active | 02-Jun-2016 | A61K39/0011 | 00 |
Ultimovacs Executive Team (10)
Ultimovacs Board Members (12)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 00000 00.0 | Self | Board Member | 000 0000 |
| 00000 00000000 000 | Self | Board Member | 000 0000 |
| 00ø00 00000000 | Gjelsten Holding | Board Member | 000 0000 |
| 000 0000000 | Ultimovacs | Board Member | 000 0000 |
| 000000 0000000 | Self | Board Member | 000 0000 |
Ultimovacs Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Ultimovacs Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Ultimovacs Investments (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000 | 30-Jan-2022 | 00000 0000 | 0000 | Entertainment Software | |
| Immuneed | 11-Jul-2018 | Buyout/LBO | 00.000 | Drug Discovery | 0000 0000 |
Ultimovacs Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000 | Drug Discovery | Uppsala, Sweden | 0000 |
Ultimovacs ESG
Risk Overview
Risk Rating
Updated July, 19, 2022
19.54 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,008
Rank
0.0
Percentile
Biotechnology
Subindustry
00 of 465
Rank
0.00
Percentile
